We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Quantitative Biomarker Panel Developed to Advance Cancer-Related Drug and Diagnostic Development

By LabMedica International staff writers
Posted on 11 Apr 2011
Print article
Through quantitative measurement of 101 cancer-related proteins, a quantitative biomarker panel provides researchers with unprecedented data on biologic pathways that could hold the key to understanding the molecular basis of cancer.

Rules-Based Medicine, Inc. (RBM; Austin, TX, USA), a provider of innovative biomarker solutions, reported the global launch of OncologyMAP, a powerful tool developed at the direction of and with funding from the US National Cancer Institute (NCI; Bethesda, MD, USA). OncologyMAP was released to a limited number of key customers in October 2010, and RBM has received positive feedback from clients who report valuable results in their studies for drug retasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service.

"The use of biomarker tools throughout drug development is a requirement for researchers who must balance leaner R&D budgets with the greater demands for safety, innovation, and success,” said Craig Benson, RBM president and CEO. "From one drop of serum, OncologyMAP can deliver data that could help solve therapeutic and diagnostic dilemmas related to cancer making this biomarker panel an essential component of the development toolkit.”

OncologyMAP provides drug researchers with an accurate and cost-effective means of evaluating the efficacy and safety of therapeutic candidates. The test is validated to clinical laboratory standards enabling biomarker pattern discoveries made in basic research to be reproducibly extended into clinical trials. The use of sensitive, reproducible biomarker patterns as objective measures of drug efficacy and toxicity can accelerate development efforts and facilitate decision-making to avoid costs associated with late-stage drug attrition.

OncologyMAP is based on RBM's proprietary multianalyte profiling (MAP) platform, which quantifies major blood-based biomarkers representing dozens of important biologic pathways. The multiplexing process allows for heightened efficiency while providing accuracy and precision.

Related Links:

Rules-Based Medicine

Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Urine Drug Test
Instant-view Methadone Urine Drug Test
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.